Thomas A. Mccarthy Purchases 10,000 Shares of Privia Health Group, Inc. (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Thomas A. Mccarthy purchased 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The stock was bought at an average cost of $16.37 per share, for a total transaction of $163,700.00. Following the purchase, the director now directly owns 52,611 shares in the company, valued at approximately $861,242.07. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Privia Health Group Price Performance

NASDAQ:PRVA opened at $17.31 on Friday. The firm’s fifty day moving average price is $18.40 and its two-hundred day moving average price is $20.64. The company has a market cap of $2.07 billion, a P/E ratio of 115.40, a P/E/G ratio of 2.37 and a beta of 0.81. Privia Health Group, Inc. has a one year low of $15.92 and a one year high of $29.42.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.13% and a net margin of 1.11%. The firm had revenue of $440.80 million for the quarter, compared to analyst estimates of $425.81 million. During the same period in the previous year, the business posted $0.14 earnings per share. The business’s revenue for the quarter was up 21.0% on a year-over-year basis. As a group, equities research analysts expect that Privia Health Group, Inc. will post 0.21 earnings per share for the current year.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors have recently made changes to their positions in PRVA. Covestor Ltd lifted its position in shares of Privia Health Group by 8.3% during the 3rd quarter. Covestor Ltd now owns 6,703 shares of the company’s stock valued at $154,000 after acquiring an additional 514 shares during the period. Yousif Capital Management LLC grew its stake in Privia Health Group by 1.1% during the fourth quarter. Yousif Capital Management LLC now owns 52,628 shares of the company’s stock worth $1,212,000 after buying an additional 563 shares in the last quarter. New York State Common Retirement Fund increased its holdings in Privia Health Group by 2.7% in the 3rd quarter. New York State Common Retirement Fund now owns 27,966 shares of the company’s stock valued at $643,000 after buying an additional 737 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Privia Health Group by 9.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,970 shares of the company’s stock valued at $176,000 after buying an additional 756 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its holdings in shares of Privia Health Group by 0.9% during the 3rd quarter. Glenmede Trust Co. NA now owns 107,711 shares of the company’s stock worth $2,477,000 after acquiring an additional 976 shares during the period. 94.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on PRVA. TD Cowen cut their target price on shares of Privia Health Group from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Friday, March 1st. JPMorgan Chase & Co. reduced their price objective on Privia Health Group from $38.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, March 6th. Evercore ISI dropped their target price on Privia Health Group from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 28th. Jefferies Financial Group initiated coverage on Privia Health Group in a report on Monday, February 26th. They set a “buy” rating and a $25.00 price target for the company. Finally, Stifel Nicolaus dropped their price objective on Privia Health Group from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Privia Health Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.08.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.